Paper35451676
Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory.
Ellingson BM and 2 others. Neurotherapeutics, 2022. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. Papers, record 35451676. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35451676
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Humans | |
| Systems Theory | |
| Magnetic Resonance Imaging | |
| Brain | |
| Drug Combinations |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P50 CA211015 | NCI NIH HHS | United States | P50CA211015 | PubMed | NIH RePORTER |
| R01 CA270027 | NCI NIH HHS | United States | R01CA270027 | PubMed and NIH | NIH RePORTER |
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8478956 | Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. | J Natl Cancer Inst | 1993 | https://conductscience.org/library/papers/8478956 | PubMed |
| 2 | 30652553 | Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival. | JCO Clin Cancer Inform | 2018 | https://conductscience.org/library/papers/30652553 | PubMed |
| 3 | 27580889 | Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. | Neuro Oncol | 2017 | https://conductscience.org/library/papers/27580889 | PubMed |
| 4 | 25672376 | Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. | Int J Oncol | 2015 | https://conductscience.org/library/papers/25672376 | PubMed |
| 5 | 32048719 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/32048719 | PubMed |
| 6 | 18847342 | Independent association of extent of resection with survival in patients with malignant brain astrocytoma. | J Neurosurg | 2009 | https://conductscience.org/library/papers/18847342 | PubMed |
| 7 | 21979382 | FSL. | Neuroimage | 2012 | https://conductscience.org/library/papers/21979382 | PubMed |
| 8 | 3385495 | A selective impairment of motion perception following lesions of the middle temporal visual area (MT). | J Neurosci | 1988 | https://conductscience.org/library/papers/3385495 | PubMed |
| 9 | 15501092 | Advances in functional and structural MR image analysis and implementation as FSL. | Neuroimage | 2004 | https://conductscience.org/library/papers/15501092 | PubMed |
| 10 | 894339 | Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. | J Neurosurg | 1977 | https://conductscience.org/library/papers/894339 | PubMed |
| 11 | 28718326 | CNS Anticancer Drug Discovery and Development: 2016 conference insights. | CNS Oncol | 2017 | https://conductscience.org/library/papers/28718326 | PubMed |
| 12 | 29040703 | Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. | Neuro Oncol | 2018 | https://conductscience.org/library/papers/29040703 | PubMed |
| 13 | 30258190 | Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. | Sci Rep | 2018 | https://conductscience.org/library/papers/30258190 | PubMed |
| 14 | 28108885 | Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. | Neurotherapeutics | 2017 | https://conductscience.org/library/papers/28108885 | PubMed |
| 15 | 3339397 | The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. | J Clin Oncol | 1988 | https://conductscience.org/library/papers/3339397 | PubMed |
| 16 | 1332459 | MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. | AJNR Am J Neuroradiol | 1992 | https://conductscience.org/library/papers/1332459 | PubMed |
| 17 | 26250565 | Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. | Neuro Oncol | 2015 | https://conductscience.org/library/papers/26250565 | PubMed |
| 18 | 23983030 | The role of human ventral visual cortex in motion perception. | Brain | 2013 | https://conductscience.org/library/papers/23983030 | PubMed |
| 19 | 24475840 | Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. | Radiology | 2014 | https://conductscience.org/library/papers/24475840 | PubMed |
| 20 | 3033172 | Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. | J Neurosurg | 1987 | https://conductscience.org/library/papers/3033172 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38808755 | Digital "flipbooks" for enhanced visual assessment of simple and complex brain tumors. | Neuro Oncol | 2024 | https://conductscience.org/library/papers/38808755 | PubMed |
| 36344725 | Therapeutic Advances in Neuro-Oncology. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/36344725 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FASTK | 10922 | PubTator's text mining | https://conductscience.org/library/genes/10922 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35451676
GET https://conductscience.org/api/papers/v1/35451676/references?page=2